Tag: KDC-MN-271

  • Tamoxifen

    Selective estrogen receptor modulator (triphenylethylene)

    Abstract

    Tamoxifen ((Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine; CAS 10540-29-1; molecular formula C26H29NO; molecular weight 371.51) is a triphenylethylene SERM developed at ICI Pharmaceuticals (now AstraZeneca) and approved by the FDA in 1977 under the trade name Nolvadex. The compound is a tissue-selective estrogen receptor modulator: antagonist in breast tissue (the basis for breast cancer indications) and partial agonist in bone, liver, and uterus. The active metabolite endoxifen (4-hydroxy-N-desmethyltamoxifen) generated via CYP2D6 is approximately 100-fold more potent than tamoxifen at ER binding and contributes substantially to clinical activity; CYP2D6 polymorphism affects clinical response. Plasma half-life is approximately 5 to 7 days for parent compound. Approved indications include adjuvant treatment of ER-positive breast cancer (premenopausal and postmenopausal), metastatic breast cancer, and breast cancer prevention in high-risk patients. Adverse events include endometrial cancer (rare), thromboembolism, and hot flashes. Used as the canonical SERM in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.